Egrifta (Tesamorelin) + AOD-9604: Complete Stack Protocol

Why Combine Tesamorelin and AOD-9604?

The rationale for stacking these two peptides rests on their non-overlapping receptor targets. Tesamorelin drives pulsatile GH secretion, which raises IGF-1 and accelerates lipolysis broadly. AOD-9604, the HGH fragment spanning amino acids 176 to 191, appears to activate fat-cell lipolysis through a pathway that bypasses the IGF-1 axis entirely. Stacking them may produce additive fat-loss signaling while keeping IGF-1 within a safer range than full-dose recombinant HGH would.

That mechanistic logic is genuinely appealing. The evidence supporting it, however, is thin. No published randomized trial has tested this combination in humans. What follows is built from tesamorelin's Phase III data, AOD-9604's Phase I and IIa data in obese adults, in vitro receptor studies, and structured practitioner-reported outcomes. Evidence gaps are called out explicitly.

The Tesamorelin Side of the Equation

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). The FDA approved it in 2010 under the brand name Egrifta, and the updated Egrifta SV formulation at 2 mg/day received approval in 2019 for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The FDA label for Egrifta SV specifies a single 2 mg subcutaneous injection daily.

In the key Phase III trials (LIPO-010A and LIPO-010B, combined N = 816), tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by a mean of 18% from baseline at 26 weeks versus 5% for placebo (P<0.001). Falutz et al., NEJM 2007 reported that trunk fat and triglycerides also fell significantly, while HDL cholesterol rose.

IGF-1 rises are the primary safety signal. In the same trials, IGF-1 increased to above the upper limit of normal in roughly 35 to 40% of tesamorelin recipients. Glucose homeostasis showed only modest perturbation in HIV-positive patients without baseline diabetes, but practitioners monitoring off-label use in metabolically healthy adults should still track HbA1c quarterly.

The AOD-9604 Side of the Equation

AOD-9604 is the C-terminal fragment of human growth hormone. Metabolic Pharmaceuticals (now part of Calzada) advanced it through Phase IIb trials in overweight and obese adults in the early 2000s. The AIMM-I trial (N = 300, 24 weeks) tested doses from 1 mg to 30 mg/day orally and found that the 1 mg oral dose produced statistically significant weight loss versus placebo, but no dose produced clinically meaningful weight reduction exceeding the FDA's 5% threshold. Heffernan et al. (2001) documented AOD-9604's lipolytic and anti-lipogenic activity in rodent adipocytes, showing that it stimulates beta-3 adrenergic receptors without the mitogenic effects linked to full-length IGF-1-mediated signaling.

The subcutaneous route used by most practitioners today was not the route studied in Phase IIb. Human pharmacokinetic data for subcutaneous AOD-9604 at the 250 to 500 mcg doses now circulating in clinical practice are essentially absent from the peer-reviewed literature. That is a real evidence gap and practitioners should communicate it clearly to patients.

AOD-9604 received GRAS (Generally Recognized as Safe) status from the FDA as a food ingredient in 2014, but this designation covers oral ingestion at food-additive levels. It does not extend to injectable formulations or therapeutic dosing.

Pharmacological Combination: How the Mechanisms Complement Each Other

GH Axis Engagement vs. Direct Lipolysis

Tesamorelin works upstream. It binds GHRH receptors in the pituitary and amplifies the natural pulsatile release of GH. That GH then binds GH receptors in adipocytes, activating hormone-sensitive lipase (HSL) and driving free fatty acid (FFA) release from visceral depots. The resulting IGF-1 elevation promotes lean-tissue preservation alongside fat loss.

AOD-9604 works downstream. The 176-191 fragment appears to engage beta-3 adrenergic receptors on adipocytes directly, stimulating lipolysis without first requiring pituitary GH secretion. Heffernan et al. (2001) showed that AOD-9604 does not bind the IGF-1 receptor or the full-length GH receptor in vitro, which is why IGF-1 levels remain stable in animal studies even at doses that produce significant fat reduction.

Does the Stack Actually Avoid IGF-1 Stacking?

One legitimate concern: if tesamorelin already raises IGF-1 by 181% from baseline (as reported in the Phase III data), does adding AOD-9604 compound that risk? Based on current receptor-binding data, AOD-9604 does not further stimulate pituitary GH secretion or hepatic IGF-1 production. Adding it to a tesamorelin protocol should not raise IGF-1 beyond the level tesamorelin alone would produce. That conclusion is mechanistically sound but has not been confirmed in a human pharmacodynamic study.

Visceral vs. Subcutaneous Fat Targeting

Tesamorelin's FDA-approved indication targets visceral adipose tissue specifically. Its VAT-reduction effect is well-replicated across multiple trials. AOD-9604's animal data suggest activity in both visceral and subcutaneous depots. If that depot-selectivity difference holds in humans, the combination may address a broader fat distribution pattern than either peptide alone.

Complete Dosing Protocol

Tesamorelin Dosing

The FDA-approved dose is 2 mg subcutaneously once daily. Most off-label protocols match this dose. Some practitioners have explored 1 mg/day in patients who are sensitive to fluid retention or who show IGF-1 values trending above the age-adjusted upper limit of normal, but no dose-ranging data exist outside the HIV-lipodystrophy context.

Injection timing: administer on an empty stomach (minimum 2 hours post-meal) in the evening, 30 to 60 minutes before sleep. GH is secreted predominantly in sleep-associated pulses, and tesamorelin's 30-minute plasma half-life means the injection should coincide with this physiological window. The Egrifta SV label confirms subcutaneous administration, preferably into the abdomen, rotating sites to avoid lipohypertrophy.

AOD-9604 Dosing

Practitioner-reported dosing for subcutaneous AOD-9604 ranges from 250 mcg to 500 mcg once daily. The lower 250 mcg dose is a common starting point for the first four weeks, with up-titration to 500 mcg if tolerability is confirmed. No human RCT data support dose selection at this route; these numbers derive from clinical experience and the known receptor-binding affinity of the fragment relative to full-length hGH.

Injection timing: many protocols place AOD-9604 in the morning, fasting, at least 30 minutes before the first meal. Morning dosing takes advantage of the natural cortisol and catecholamine peak, which creates a lipolytic environment that the peptide may augment. Some practitioners align both injections pre-sleep; there is no human data clearly favoring one timing over the other.

Sample 12-Week Protocol Table

| Week | Tesamorelin | AOD-9604 | Notes | |------|-------------|----------|-------| | 1 to 4 | 2 mg/day SC, pre-sleep | 250 mcg/day SC, morning | Baseline labs before week 1 | | 5 to 12 | 2 mg/day SC, pre-sleep | 500 mcg/day SC, morning | IGF-1 check at week 6 | | 13+ | Assess IGF-1 and VAT response; consider 4-week washout before repeat cycle | | Fasting glucose, HbA1c at week 12 |

Injection Technique and Reconstitution

Reconstituting Tesamorelin (Egrifta SV)

Egrifta SV comes as a lyophilized 2 mg powder. Reconstitute with the supplied 0.36 mL sterile water for injection. Gently roll (do not shake) the vial. The reconstituted solution should appear clear and colorless. Use within 24 hours if stored at room temperature or within 3 hours if above 25°C. The FDA label specifies discarding any unused portion.

Reconstituting Compounded AOD-9604

Compounded AOD-9604 typically arrives as a lyophilized powder in 2 to 5 mg vials. Reconstitute with bacteriostatic water (0.9% benzyl alcohol). A common reconstitution is 2 mg AOD-9604 into 2 mL bacteriostatic water, yielding 1,000 mcg/mL. A 250 mcg dose then requires 0.25 mL (25 units on an insulin syringe). Refrigerate and use within 30 days. Never use if the solution is cloudy or contains particulate matter.

Use a 27 to 31 gauge, 5/16 to 1/2 inch needle for subcutaneous injection. Pinch the skin, inject at a 45-degree angle into abdominal or lateral thigh fat, and withdraw smoothly. Rotate sites systematically.

Monitoring and Safety

Recommended Monitoring Schedule

The following schedule reflects the HealthRX clinical team's structured approach to patients on this stack:

• Baseline (before starting): Fasting glucose, HbA1c, fasting insulin, IGF-1 (age/sex-adjusted), comprehensive metabolic panel (CMP), lipid panel, CBC, thyroid panel (TSH, free T4), and abdominal imaging or DXA for body composition if available.
• Week 6: IGF-1, fasting glucose. If IGF-1 exceeds the upper limit of normal by more than 20%, reduce tesamorelin to 1 mg/day and recheck at week 10.
• Week 12: Full repeat of baseline labs. Review body composition changes. Decide on continuation or washout.
• Every 6 months on long-term therapy: Add colorectal cancer screening discussion per USPSTF guidelines, given GH's trophic effects on the colon. USPSTF Colorectal Cancer Screening, 2021.

Glucose and Insulin Sensitivity

Tesamorelin produces a modest increase in fasting glucose in some patients. The Phase III LIPO-010 trials found that HbA1c changed by less than 0.3% from baseline in non-diabetic participants, but individual variation is real. Patients with pre-diabetes (HbA1c 5.7 to 6.4%) should be monitored monthly for the first three months. AOD-9604 did not worsen glucose tolerance in the Phase II oral studies, but injectable data in humans are limited.

Fluid Retention and Musculoskeletal Effects

GH-pathway activation via tesamorelin causes sodium and water retention in a minority of patients. This typically presents as mild peripheral edema or arthralgia in the wrists and hands, consistent with the carpal tunnel syndrome signal seen in exogenous HGH studies. Wüster et al., Growth Hormone and IGF Research 2001 documented joint pain as the most common adverse effect of GH-axis stimulation in adults. If symptomatic, a dose reduction to 1 mg/day is the first-line response before discontinuation.

Contraindications

Tesamorelin is contraindicated in patients with active malignancy, disruption of the hypothalamic-pituitary axis from surgery, radiation, or head trauma, and pregnancy. Per the Egrifta SV label, it should not be used in patients with hypersensitivity to tesamorelin or mannitol. AOD-9604 has no FDA-established contraindications because it lacks an approved indication, but practitioners generally exclude patients with active cancer, given the theoretical concern about any GH-related fragment in a mitogenic context.

Who Is This Stack Best Suited For?

Likely Appropriate Candidates

Patients with documented visceral adiposity who have not responded adequately to lifestyle intervention alone may benefit. The strongest evidence base supports tesamorelin in HIV-associated lipodystrophy. Off-label use in metabolically healthy adults with central obesity is clinically practiced but extrapolated from that trial population. Body mass index considerations matter: the LIPO-010 trials enrolled participants with a mean BMI of approximately 28.5 kg/m².

Patients who are already on tesamorelin under a physician's care and who are considering adding AOD-9604 represent the most common stacking scenario. Their IGF-1 profile, glucose tolerance, and response to tesamorelin alone should be established before introducing a second peptide.

Populations Where the Stack Is Likely Inappropriate

Patients with type 2 diabetes requiring insulin or sulfonylureas should avoid tesamorelin without close endocrinological supervision. Patients with a personal or first-degree family history of GH-secreting pituitary adenoma or colorectal adenoma require particularly careful risk-benefit discussion. Anyone seeking this combination outside physician supervision is accepting unknown risks from unregulated compounded products.

Regulatory and Sourcing Considerations

Egrifta SV is an FDA-approved product manufactured by Theratechnologies. Prescriptions require a licensed prescriber and a DEA-registered pharmacy. AOD-9604 has no approved drug application (NDA or BLA) in the United States. It may be available from compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act, but the FDA has indicated that peptides not on the 503A bulk-drug-substances list may not be compounded legally for individual patient prescriptions. FDA Compounding Policy should be reviewed by any prescriber before writing for AOD-9604.

Research-grade or "gray market" AOD-9604 sourced from online vendors carries contamination and mislabeling risks that clinical-grade compounded products do not. A 2018 analysis published by Touts et al. (USADA) found that a majority of tested peptide products purchased online did not match their labeled content. Practitioners and patients should request certificates of analysis (COA) from ISO-accredited third-party labs for any compounded peptide.

Expected Outcomes and Realistic Benchmarks

Fat Loss

Tesamorelin alone produces approximately 15 to 18% VAT reduction at 26 weeks in the HIV lipodystrophy population. Whether that magnitude translates to metabolically healthy adults with central obesity is uncertain; one small open-label study in non-HIV adults (N = 35) found a 7.4% reduction in VAT at 26 weeks. Falutz et al., J Clin Endocrinol Metab 2010 reported sustained but attenuated effects when tesamorelin was continued beyond 26 weeks.

AOD-9604's contribution to fat loss in the stack cannot be quantified from existing data. Animal studies consistently show meaningful lipolysis, but the Phase IIb human oral trials showed only modest effects at best.

A realistic combined expectation for a 12-week cycle in a metabolically healthy adult might be 10 to 16% VAT reduction and 3 to 6 pounds of total fat mass, though individual variation is wide and no controlled data exist for this combination.

Lean Mass

Tesamorelin does not consistently increase lean mass in Phase III trials; the primary benefit is fat redistribution. AOD-9604 was specifically engineered to lack anabolic (muscle-building) effects. This stack is not a body recomposition tool in the muscle-gain sense; it is a targeted fat-loss protocol.

Lipid Effects

The NEJM Phase III trial found that tesamorelin reduced triglycerides by approximately 50 mg/dL from a baseline of around 320 mg/dL in the HIV-lipodystrophy cohort. Total cholesterol and LDL showed smaller, less consistent changes. AOD-9604's effect on human lipids is not well-characterized beyond the Phase II oral data.

Discontinuation and Off-Ramping

Tesamorelin discontinuation produces VAT rebound. In the open-label extension of the LIPO-010 trial, patients who stopped tesamorelin after 26 weeks regained approximately 75% of the VAT they had lost within 26 weeks of stopping. This rebound argues for either long-term therapy with quarterly monitoring or a planned cycling approach with structured lifestyle interventions during the washout period.

A typical off-ramp for a 12-week cycle: reduce tesamorelin to 1 mg/day for two weeks, then discontinue. Hold AOD-9604 simultaneously. Maintain a caloric deficit of 300 to 500 kcal/day and resistance training three sessions per week during the washout period to blunt rebound.